Close

Brean Murray Carret & Co Increases Price Target on ARIAD (ARIA) to $35

October 1, 2012 1:56 PM EDT
Get Alerts ARIA Hot Sheet
Price: $23.99 --0%

Rating Summary:
    10 Buy, 12 Hold, 3 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 10 | Down: 11 | New: 7
Join SI Premium – FREE
Brean Murray Carret & Co. reiterated a Buy rating on ARIAD Pharmaceuticals (NASDAQ: ARIA) and increased their price target to $35.00 (from $19.00).

“Ariad presented positive interim Phase 1 data at the Congress of the European Society for Medical Oncology from the ongoing Phase 1 portion of its Phase 1/2 trial of AP26113 in patients with advanced solid tumors, most of whom (29/34) were non-small cell lung cancer (NSCLC) patients,” said analyst Jonathan Aschoff.

He considers the AP26113 data to be highly encouraging and noted a parallel between AP26113 and ponatinib, which increases his optimism of a second Ariad drug taking an abbreviated path to market.

For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals click here. For more ratings news on ARIAD Pharmaceuticals click here.

Shares of ARIAD Pharmaceuticals closed at $24.21 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Brean Murray Carret & Co., Raising Prices